|会社名||Hologic Inc （ホロジック）|
|分野（sector）||Health Care ヘルスケア|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 ホロジック(Hologic Inc.)は女性のヘルスケアニーズに応える診断製品、医療用画像処理システム及び外科製品の開発・製造・提供に従事する会社。同社は診断、乳房健康、産婦人科(GYN)手術及び骨格健康という4つの事業部門を運営する。同社の診断製品は、APTIMAアッセイ系製品、ThinPrepシステム、ラピッド胎児性フィブロネクチン及びProcleix血液スクリーニングアッセイを含む。同社はB型肝炎ウイルス(HBV)、C型肝炎ウイルス(HCV)及びヒト免疫不全ウイルス-1(HIV-1)の定量のためのウイルス負荷のアッセイを提供する。乳房健康の製品は、デジタル式乳房撮影システム、コンピュータ支援診断(CAD)及び乳房生検のガイダンスシステムなどの乳房画像と関連する製品・アクセサリーを含む。GYN手術製品は、NovaSure子宮内膜アブレーションシステムとMyoSure子宮筋腫切除システムを含む。骨格健康部門は、Discovery・Horizon X線骨密度測定装置とミニCアーム撮像システムを提供する。 ホロジックは米国の医療機器製造会社。遺伝子関連試薬、医薬品、診断薬、医療機器、理化学機器などの研究開発・製造・販売を手掛ける。主な製品は｢NovaSure｣子宮内膜アブレ―ションシステムや｢MyoSure｣子宮筋腫除去システム、ホライゾン骨濃度計など。本社はマサチュ―セッツ州ベッドフォ―ド。 Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.|
|本社所在地||250 Campus Drive Marlborough MA 01752 USA|
|代表者氏名||Stephen P. MacMillan スティーブン・P・マクミラン|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the nine months ended 30 June 2018 Hologic Inc. revenues increased 7% to $2.4B. Net loss before extraordinary items totaled $516.3M vs. income of $672.8M. Revenues reflect Medical Aesthetics segment increase from $126M to $268.5M Breast Health segment increase of 7% to $896M Skeltal Health segment increase of 4% to $66.8M Europe segment increase of 27% to $284.4M United States segment increase of 2% to $1.8B.|
Bone Densitometer Market Share Forecast to Witness Considerable Growth from 2020 to 2030 - Hologic, DMS Imaging, Medonica Co LTD 2020/11/13 07:33:42 OpenPR
Bone densitometer is also known as DXA, DEXA, and also dual-energy x-ray absorpiometry. It makes use of ionizing radiation for generating pictures or images to understand more deeply about the patient’s internal body. Physicians generally look for the lower lumbar,
Global Cellulite Treatment Market In-Depth Insight Of Sales Analysis, Growth Forecast And Upcoming Trends Opportunities By Inceler Medikal Co Ltd., Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Hologic Inc, Candela Corporation 2020/11/10 17:07:22 OpenPR
Data Bridge Market Research Adds “Global Cellulite Treatment Market – Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages : 350 No of Figures: 60 No of Tables: 220 in
Body Fat Measurement Market Revolutionary Opportunities 2025 | GE Healthcare, AccuFitness LLC, Hologic, Inc., COSMED Srl 2020/11/06 11:33:30 OpenPR
Global Body Fat Measurement Market: Overview Body fat analyzers, referred to as impedance meters, are tools to measure body fat and uncover risks associated with it. They also help in assessing the effectiveness of exercise, nutrition intake, and age related issues.
Hologic’s diagnostic sales rocket 375% as COVID-19 demand continues to rise 2020/11/05 16:01:22 FierceBiotech
After seeing its overall sales slip last quarter, Hologic’s COVID-19 testing sales have continued to skyrocket—powering the company’s most recent quarterly income to over $1.3 billion.
The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping 2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
Hologic Earnings Report: Here’s what to expect from Stock market Insights & financial analysis 2020/11/04 12:12:00 Stock Market Daily
Hologic announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Rapid Cancer Tests Market 2020 Precise Outlook – Abingdon Health, Hologic, Abbott, NanoEntek, Biomerica, Alfa Scientific Designs, Exact Sciences, Biosynex 2020/11/03 08:10:09 OpenPR
The Rapid Cancer Tests Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic
Transplant Diagnostics Market Account To US$ 1,542.89 Mn By 2027 By Top Players Like Thermo Fisher Scientific, Abbott, Illumina, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, bioMérieux SA, QIAGEN, Hologic, Luminex Corporation and Omixon and others 2020/11/03 06:56:21 OpenPR
A report by The Insight Partner's on the Transplant Diagnostics Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
There are 12 coronavirus tests you can use from home. Here's how they work and where to order one. 2020/11/02 22:02:00 Business Insider
Summary List Placement Among the hundreds of tests out there for the novel coronavirus, just a handful have received emergency authorization from the US Food and Drug Administration to ship them to people's homes. With at-home tests, people self-collect their samples and send them back to the testing company for analysis. Several companies are developing tests that can work fully at home without shipping and lab equipment involved, but they haven't received the FDA's go-ahead yet. Still, ordering a test from the comfort of home can be appealing. It not only avoids run-ins with the physical healthcare system, saving time, but also reduces the risk of spreading the virus or getting infected yourself. Lab giant Quest Diagnostics has sold about half a million home tests, though that number includes self-collected samples taken in drive-thrus, the company told Business Insider in October. As of June, Fulgent Genetics, another testing group, said it was processing thousands of the home kits per day.
HHS and DOD Announce $119 Million Contract to Hologic to Better Meet the Demand of COVID-19 Testing 2020/10/31 00:17:39 US Department of Health & Human Services
Today, as part of an ongoing collaboration between the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DOD), the two departments awarded Hologic, Inc. a $119 million contract to establish additional domestic production to increase diagnostic testing capacity for SARS-CoV-2.
Aptima® HIV-1 Quant Dx Assay Awarded WHO Prequalification for Dried Blood Spot Samples 2020/09/15 14:57:15 South Africa Today
MARLBOROUGH, Mass.–(BUSINESS WIRE/AETOSWire)– Hologic, Inc. (Nasdaq: HOLX) announced today that its CE-marked Aptima® HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for testing of dried blood spot (DBS) samples. The Aptima® HIV-1 Quant Dx assay can be used with DBS samples to monitor viral load and disease progression among HIV-1 infected individuals, and […] The post Aptima® HIV-1 Quant Dx Assay Awarded WHO Prequalification for Dried Blood Spot Samples appeared first on South Africa Today .
High-End-Ultraschallsysteme von SuperSonic Imagine jetzt Teil von Hologic 2020/09/15 08:30:00 Business Wire
MÜNCHEN--(BUSINESS WIRE)--SuperSonic Imagine ist auf dem deutschen, schweizerischen und österreichischen Markt jetzt Teil von Hologic, dem weltweit führenden Anbieter von Lösungen für die Frauengesundheit. SuperSonic Imagine ist ein Pionier auf dem Gebiet der innovativen Ultraschall-Bildgebung und Entwickler der ShearWave™ Elastographie. Damit erweitert Hologic sein Portfolio an innovativen Hochleistungs-Bildgebungs-Lösungen um die Aixplorer MACH©-Ultraschallsysteme. Es zeichnet sich durch eine
Hologic prices $950 debt offering (NASDAQ:HOLX) 2020/09/15 04:56:39 Seeking Alpha
Hologic (NASDAQ:HOLX) has priced its $950M of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000. Proceeds of the offering and available c
Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029 2020/09/14 22:52:00 Business Wire
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029